Safety-Related Labeling Changes
Gastrointestinal Disorders: diarrhea, salivary hypersecretion, acute pancreatitis with onset within 48 hours after GBCA administration.
Trade Name
Dotarem
Updated Section
4.8. Undesirable effects
Month
Jan, 2026